Roche weathers early biosimilar attacks on US cancer sales
Roche weathers early biosimilar attacks on legacy US cancer drugs but warns of “significant impact” to come.
Roche weathers early biosimilar attacks on legacy US cancer drugs but warns of “significant impact” to come.